Mark W. Drummond

3.5k total citations · 1 hit paper
52 papers, 1.5k citations indexed

About

Mark W. Drummond is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Mark W. Drummond has authored 52 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Hematology, 31 papers in Genetics and 12 papers in Rheumatology. Recurrent topics in Mark W. Drummond's work include Chronic Myeloid Leukemia Treatments (23 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (19 papers) and Acute Myeloid Leukemia Research (15 papers). Mark W. Drummond is often cited by papers focused on Chronic Myeloid Leukemia Treatments (23 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (19 papers) and Acute Myeloid Leukemia Research (15 papers). Mark W. Drummond collaborates with scholars based in United Kingdom, United States and Italy. Mark W. Drummond's co-authors include Claire Harrison, Tessa L. Holyoake, Ruben A. Mesa, Alessandro M. Vannucchi, Francisco Cervantes, Elena Mishchenko, Mindaugas Jurgutis, Tamás Masszi, Éric Jourdan and Jason Gotlib and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Mark W. Drummond

48 papers receiving 1.5k citations

Hit Papers

Safety and Efficacy of Fedratinib in Patients With Primar... 2015 2026 2018 2022 2015 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
    2015 340 citations Claire Harrison, Francisco Cervantes et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark W. Drummond United Kingdom 17 1.0k 946 627 435 212 52 1.5k
Veronika Buxhofer‐Ausch Austria 19 1.4k 1.4× 1.1k 1.1× 946 1.5× 665 1.5× 249 1.2× 64 2.0k
Aaron Weitzman United States 15 570 0.6× 687 0.7× 181 0.3× 421 1.0× 329 1.6× 38 1.2k
Maximilian Stahl United States 25 387 0.4× 1.3k 1.3× 970 1.5× 66 0.2× 466 2.2× 121 2.0k
Andrija Bogdanović Serbia 17 279 0.3× 466 0.5× 294 0.5× 69 0.2× 141 0.7× 96 894
Halyna Pylypenko Czechia 11 389 0.4× 747 0.8× 736 1.2× 52 0.1× 672 3.2× 29 1.3k
Carmen Chillón Spain 25 354 0.3× 793 0.8× 715 1.1× 66 0.2× 387 1.8× 76 1.5k
Tracy Cardillo United States 9 172 0.2× 252 0.3× 122 0.2× 547 1.3× 200 0.9× 13 1.1k
Mario Masi Italy 17 429 0.4× 1.1k 1.2× 488 0.8× 75 0.2× 220 1.0× 23 1.6k
Lionel Karlin France 22 313 0.3× 922 1.0× 956 1.5× 29 0.1× 746 3.5× 101 1.8k
Sabine Käyser Germany 23 770 0.7× 2.2k 2.3× 1.4k 2.3× 23 0.1× 366 1.7× 64 3.1k

Countries citing papers authored by Mark W. Drummond

Since Specialization
Citations

This map shows the geographic impact of Mark W. Drummond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark W. Drummond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark W. Drummond more than expected).

Fields of papers citing papers by Mark W. Drummond

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark W. Drummond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark W. Drummond. The network helps show where Mark W. Drummond may publish in the future.

Co-authorship network of co-authors of Mark W. Drummond

This figure shows the co-authorship network connecting the top 25 collaborators of Mark W. Drummond. A scholar is included among the top collaborators of Mark W. Drummond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark W. Drummond. Mark W. Drummond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Drummond, Mark W., Carlo Finelli, Fjoralba Kristo, et al.. (2025). Real-World Treatment Patterns, Clinical Outcomes, and Costs in Patients with Higher-Risk Myelodysplastic Syndromes Across France, Germany, and the United Kingdom. Journal of Blood Medicine. Volume 16. 307–319.
2.
Sarocchi, Matteo, Junmin Li, Depei Wu, et al.. (2024). Cardiac effects of deferasirox in transfusion‐dependent patients with myelodysplastic syndromes: TELESTO study. British Journal of Haematology. 204(5). 2049–2056. 3 indexed citations
3.
Radia, Deepti, Jason Gotlib, Mark W. Drummond, et al.. (2022). Avapritinib As First-Line Therapy in Patients with Advanced Systemic Mastocytosis: Efficacy and Safety from the Pathfinder Clinical Study. Blood. 140(Supplement 1). 1509–1511. 1 indexed citations
4.
DeAngelo, Daniel J., Deepti Radia, Tracy I. George, et al.. (2021). Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nature Medicine. 27(12). 2183–2191. 88 indexed citations
5.
Loke, Justin, Marlen Metzner, Rebecca H. Boucher, et al.. (2021). Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy. British Journal of Haematology. 196(2). 368–373. 3 indexed citations
6.
Burnett, Alan K., Nigel H. Russell, Robert K. Hills, et al.. (2020). Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. Journal of Clinical Oncology. 39(8). 890–901. 19 indexed citations
7.
8.
9.
10.
Killick, Sally, CG Carter, Dominic Culligan, et al.. (2013). Guidelines for the diagnosis and management of adult myelodysplastic syndromes. British Journal of Haematology. 164(4). 503–525. 63 indexed citations
11.
Todd, Marie, et al.. (2010). Primary Lymphedema and Acute Leukemia - Is There A Link?. ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam).
12.
Harrison, Claire, D. Bareford, Nauman M. Butt, et al.. (2010). Guideline for investigation and management of adults and children presenting with a thrombocytosis. British Journal of Haematology. 149(3). 352–375. 204 indexed citations
13.
Milojković, Dragana, Emma Nicholson, Jane F. Apperley, et al.. (2009). Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica. 95(2). 224–231. 80 indexed citations
14.
Barlow, Andrew, et al.. (2008). Isolated central nervous system lymphoid blast crisis in chronic myeloid leukaemia in major molecular remission. British Journal of Haematology. 142(3). 327–327. 8 indexed citations
15.
Gallipoli, Paolo, Mark W. Drummond, & Mike Leach. (2008). Hemophagocytosis and relapsed peripheral T‐cell lymphoma. European Journal Of Haematology. 82(3). 246–246. 3 indexed citations
16.
Drummond, Mark W., Anne Lennard, Tim H. Brümmendorf, & Tessa L. Holyoake. (2004). Telomere Shortening Correlates with Prognostic Score at Diagnosis and Proceeds Rapidly during Progression of Chronic Myeloid Leukemia. Leukemia & lymphoma. 45(9). 1775–1781. 41 indexed citations
17.
Drummond, Mark W., David Marin, Richard E. Clark, et al.. (2003). Mobilization of Ph chromosome‐negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate‐induced complete cytogenetic remission. British Journal of Haematology. 123(3). 479–483. 14 indexed citations
18.
Feng, Liang, Mark W. Drummond, Jenny Byrne, et al.. (2002). Molecular monitoring of complete cytogenetic responders following treatment with imatinib (STI571, Gleevec) for CML: A report from the UKSTI571 study group.. Blood. 100(11). 1425. 7 indexed citations
19.
Drummond, Mark W. & Tessa L. Holyoake. (2001). Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good?. Blood Reviews. 15(2). 85–95. 19 indexed citations
20.
Drummond, Mark W., et al.. (1993). Reaction-First Search.. International Joint Conference on Artificial Intelligence. 1408–1415. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Veronika Buxhofer‐Ausch Breakdown of academic impact, for papers by Aaron Weitzman Breakdown of academic impact, for papers by Maximilian Stahl Breakdown of academic impact, for papers by Andrija Bogdanović Breakdown of academic impact, for papers by Halyna Pylypenko Breakdown of academic impact, for papers by Carmen Chillón Breakdown of academic impact, for papers by Tracy Cardillo Breakdown of academic impact, for papers by Mario Masi Breakdown of academic impact, for papers by Lionel Karlin Breakdown of academic impact, for papers by Sabine Käyser
Rankless by CCL
2026